Hyperphosphorylated tau in SY5Y cells: similarities and dissimilarities to abnormally hyperphosphorylated tau from Alzheimer disease brain  by Zhong, J et al.
Hyperphosphorylated tau in SY5Y cells : similarities and dissimilarities to
abnormally hyperphosphorylated tau from Alzheimer disease brain
J. Zhong, K. Iqbal, I. Grundke-Iqbal*
NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
Received 22 March 1999; received in revised form 14 May 1999
Abstract Unlike normal tau, abnormally hyperphosphorylated
tau (AD P-tau) from Alzheimer disease (AD) does not promote
but instead inhibits microtubule assembly and disrupts already
formed microtubules. Tau in the human neuroblastoma cell line
SH-SY5Y is hyperphosphorylated at several of the same sites as
AD P-tau, and accumulates in the cell body without any
association to the cellular microtubule network. The aim of the
present study was to elucidate why the SY5Y tau does not affect
the viability of the cells. We found that, like AD P-tau, SY5Y
tau because of hyperphosphorylation does not bind to micro-
tubules and inhibits the tau-promoted assembly of microtubules.
However, the tau/HMW MAP ratio is about 10 times less in
SY5Y cells than in AD brain. These findings suggest that the
hyperphosphorylated tau from SY5Y cells has similar biological
characteristics as AD P-tau from AD brain, but is not lethal to
the SY5Y cells because of its low tau/HMW MAP ratio.
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1. Introduction
The abnormally hyperphosphorylated microtubule-associ-
ated protein (MAP) tau is the major protein component of
the paired helical ¢laments, a hallmark lesion of Alzheimer
disease (AD) [1^3]. In the AD brain, tau protein occurs in
three forms: (i) cytosolic normally phosphorylated tau (C-
tau), (ii) soluble abnormally hyperphosphorylated tau (AD
P-tau), and (iii) abnormally hyperphosphorylated tau polym-
erized into paired helical ¢laments (PHF). The C-tau has
normal microtubule assembly activity [4]. The hyperphos-
phorylated tau has not only lost its ability to bind to micro-
tubules and to promote microtubule assembly, but instead it
sequesters both normal tau and high molecular weight
(HMW) MAPs which result in the disassembly of microtu-
bules in vitro [5,6]. AD P-tau can be dephosphorylated in
vitro by protein phosphatase-1 [7], -2A [8], and -2B [9], which
restores its microtubule assembly activity [10]. SH-SY5Y hu-
man neuroblastoma cells only contain one fetal isoform of
tau, tau-352, with three microtubule binding repeats and no
N-terminal insert. Previous studies showed that tau in SY5Y
cells (SY5Y tau) when cultured in medium with 5% fetal calf
serum is hyperphosphorylated at several of the same sites as
AD P-tau. The SY5Y tau, like AD P-tau in AD, accumulates
in the cell body and does not associate to the cellular micro-
tubule network in situ or bind to taxol-stabilized microtubules
in vitro [11]. However, unlike neurons in the AD brain, SY5Y
cells have an intact microtubule network and grow normally
in low serum concentration.
The present study was undertaken to elucidate why, in con-
trast to AD P-tau, SY5Y tau does not disrupt the cellular
network. We show that SY5Y tau is hyperphosphorylated at
several sites examined to a degree comparable to AD P-tau,
and that it inhibits the tau-promoted microtubule assembly.
This ability to inhibit microtubule assembly can be reversed
by dephosphorylation, but its concentration in SY5Y cells is
only one tenth of that of tau in AD brain. In contrast, the
levels of the HMW MAPs in SY5Y cells are comparable to
those in the AD brain. These data suggest that the hyper-
phosphorylated tau from living SY5Y cells has similar bio-
logical characteristics as AD P-tau from AD brain, but is not
lethal to the SY5Y cells because of its low tau to HMW
MAPs ratio.
2. Materials and methods
2.1. Antibodies and reagents
The following phosphorylation-dependent anti-tau antibodies were
employed: Tau-1, 1:50 000 (Ser-195, 198, 199 or 202) [12,13]; PHF-1,
1:250 (P-Ser-396/404) [14,15] and 12E8 (P-Ser-262/356, 1:500) [16].
Other primary antibodies used were anti-MAP1B (3G5, 1:250),
anti-MAP1 (1:1000, Chemicon, Temecula, CA) and anti-MAP2
(1:1000, CalBiochem, La Jolla, CA). Alkaline phosphatase-conju-
gated anti-mouse or anti-rabbit IgG antibodies (1:30 000, Sigma, St.
Louis, MO), and 125I-conjugated anti-mouse or anti-rabbit IgG
(0.1 Wg/ml, Amersham, Arlington Heights, IL) were used as secondary
antibodies. Recombinant tau, tau410 (three microtubule binding do-
mains with two N-terminal inserts) was prepared as previously de-
scribed [17]. AD P-tau was prepared by the method of Ko¤pke et al.
[18]. GTP, taxol and alkaline phosphatase were purchased from Sigma
(St. Louis, MO). Phenyl Sepharose high performance hydrophobic
column was purchased from Pharmacia Biotech (Uppsala, Sweden).
2.2. Cell culture
SH-SY5Y human neuroblastoma cells were obtained from Dr. June
L. Biedler (Sloan Kettering Institute, New York). Cells were cultured
up to 70^80% con£uence in 100 mm dishes at 5% CO2 and 37‡C in D-
MEM/F-12 medium (Gibco BRL, Gaithersburg, MD) with 5% fetal
calf serum (FCS Gibco), 100 IU/ml of penicillin and 100 Wg/ml of
streptomycin. The medium was changed every 2 days. For harvesting,
the cells were ¢rst washed with warm PBS and then collected by
triturating.
2.3. Partial puri¢cation of tau from SY5Y cells
Cells were lysed on ice in a Te£on/glass homogenizer (20 strokes) in
100 mM MES, pH 6.8, 1 mM MgCl2, 1 mM EGTA, 25 mM NaF,
1 mM NaVO3, 1 mM PMSF, 5 Wg/ml leupeptin, 5 Wg/ml aprotinin,
2 Wg/ml pepstatin, 25 Wg/ml phosphoramidon, kept on ice for 20 min
and centrifuged at 100 000Ug for 30 min at 4‡C. The supernatant was
heated in a boiling water bath for 5 min and centrifuged again at
100 000Ug for 20 min. The heat-stable supernatant (heat-stable frac-
tion) was adjusted to 2 M NaCl with 5 M NaCl, and was loaded on a
phenyl Sepharose hydrophobic column (2 mg protein/ml medium),
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which was pre-equilibrated with MES bu¡er (100 mM MES, pH 6.8,
1 mM MgCl2, 1 mM EGTA) containing 2 M NaCl. The column was
washed with about two times the column volume of MES bu¡er
containing 2 M NaCl. The loading and wash fractions were pooled
and dialyzed against MES bu¡er for 24 h, and concentrated by cen-
trifugation in Centricon ¢lter (Amicon, Beverly, MA). This partially
puri¢ed SY5Y tau is called ‘SY5Y tau’ in the following. The proteins
bound to the column were eluted with MES bu¡er without NaCl and
dialyzed, and are called ‘eluate’.
2.4. In vitro dephosphorylation
SY5Y tau was dephosphorylated in vitro as previously described
[4]. Brie£y, after dialysis against 0.1 M Tris (pH 8.0), the sample was
adjusted to 0.4 mg/ml protein and incubated with alkaline phospha-
tase (200 U/ml) in a mixture of protease inhibitors (5 Wg/ml leupeptin,
5 Wg/ml aprotinin, 2 Wg/ml pepstatin, 25 Wg/ml phosphoramidon,
1 mM PMSF) at 37‡C for 16 h. The sample was then boiled for
5 min to inactivate the alkaline phosphatase, centrifuged at
15 000Ug for 10 min, dialyzed against 100 mM MES (pH 6.8),
1 mM MgCl2 and 1 mM EGTA (MES bu¡er) for 15 h, concentrated
by Centricon ¢ltration and the tau levels determined by radioimmu-
nodot-blot.
2.5. Isolation of tubulin
Bovine brain tubulin was isolated through two temperature-depend-
ent cycles of microtubule polymerization-depolymerization [19] fol-
lowed by phosphocellulose ion-exchange column chromatography
[20]. Taxol-stabilized microtubules were then prepared by incubation
of 1 mg tubulin/ml with 20 WM taxol at 37‡C for 30 min.
2.6. Microtubule binding assay
SY5Y tau (0.6 Wg) with and without pretreatment with alkaline
phosphatase was incubated with 50 Wg of taxol-stabilized microtu-
bules in 100 Wl MES bu¡er containing 10 WM taxol at 37‡C for
30 min. The microtubule pellet was separated by centrifugation over
a cushion of 100 Wl 10% sucrose in MES bu¡er containing 10 WM
taxol at 60 000Ug for 30 min. The supernatant containing the un-
bound proteins and the pellet of stabilized microtubules with micro-
tubule-bound proteins were analyzed by Western blots.
2.7. Microtubule assembly assay
Recombinant tau (100 Wg/ml) was added at 4‡C to puri¢ed bovine
tubulin (2 mg/ml) and 1 mM GTP in polymerization bu¡er (100 mM
MES, pH 6.8, 1 mM EGTA, 1 mM MgCl2). After rapid mixing, the
samples were pipetted into quartz microcuvettes and incubated at
37‡C in a thermostatically controlled Cary 1 recording spectropho-
tometer. The turbidity was continuously monitored at 350 nm. For
the inhibition assay, AD P-tau or SY5Y tau was added together with
recombinant tau. The state of microtubule assembly was further con-
¢rmed by negative-stain electron microscopy [21].
2.8. Protein determination, Western blots and radioimmunodot-blot
The protein concentration of the samples was determined by the
modi¢ed Lowry method [22]. Sample preparation and Western blots
were performed as previously described [23]. Levels of tau and HMW
MAPs in SY5Y cells and AD brain were determined by radioimmu-
nodot-blot assay as described previously [11,24]. Brie£y, cells and
brain tissue homogenates were boiled in 1% SDS and 1% L-mercap-
toethanol for 10 min followed by centrifugation at 15 000Ug for
20 min at 4‡C. Triplicate samples containing 1 Wg, 2 Wg and 4 Wg
protein each in 5 Wl were applied to nitrocellulose membrane
(Schleicher and Schuell, Keene, NH). After drying at 37‡C for 1 h,
the membranes were incubated with primary antibodies at room tem-
perature for 6 h. The blots were then developed with 125I-labeled anti-
mouse antibody (Amersham), and the radioactivity of the blots was
quanti¢ed using Fuji Bio Image Analyzer 1500 (Raytest USA Inc.,
Wilmington, DE) equipped with the Tina software system.
3. Results
3.1. Separation of tau from SY5Y cells
To study in vitro the biological activity of SY5Y tau, it was
of high signi¢cance to separate tau from other MAPs. After
heat treatment of cell extracts, tau was enriched in the heat-
stable fraction. However, Western blot analysis revealed that
this fraction contained strong MAP2 and some residual
MAP1 immunoreactivity. These MAPs were separated from
tau by phenyl Sepharose hydrophobic chromatography where
tau was in the unbound and MAP1B and MAP2 in the bound
fraction (Fig. 1A). Western blots revealed that SY5Y tau was
highly phosphorylated at the Tau-1, PHF-1, and 12E8 sites
(Fig. 1B). Radioimmunoassays showed that the phosphoryla-
tion at the Tau-1 site was 73 þ 8% in SY5Y tau compared to
s 95% in AD P-tau. Phosphorylation of SY5Y tau at 12E8
and PHF-1 sites was 77 þ 18% and 44 þ 11% respectively of
that of AD P-tau. After in vitro dephosphorylation with al-
kaline phosphatase, the phosphorylation at these sites was
fully eliminated, the Tau-1 immunoactivity increased with a
concomitant increase of the electrophoretic mobility of tau,
and the PHF-1 and 12E8 immunoactivities were negative
(these two antibodies recognize phosphorylated tau).
Fig. 1. A: Separation of HMW MAPs and SY5Y tau by phenyl
Sepharose chromatography. The heat-stable fraction (2 Wg, lane 1)
of the cell extract was applied to the column and separated into un-
bound (1 Wg, lane 2) and bound (1 Wg, lane 3) fractions. Human
brain homogenate (10 Wg, lane 4) was used as positive control of
HMW MAPs. Western blots were developed with MAP2 (1:1000)
and MAP1B (3G5, 1:250) and tau (92e, 1:5000) antibodies.
MAP1B and MAP2 bound quantitatively to the column whereas
tau was not bound and free of high molecular weight MAPs. B:
Western blots of puri¢ed SY5Y tau. SY5Y tau isolated by phenyl
Sepharose chromatography was electrophoresed on 10% SDS-PAGE
1 Wg/lane with (+) or without (3) in vitro dephosphorylation. After
electroblotting, the membranes were immunodeveloped with phos-
phorylation dependent antibodies Tau-1 (1:50 000), PHF-1 (1:250),
or 12E8 (1:500). With the conditions used, tau can be fully dephos-
phorylated in vitro at the epitopes shown.
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3.2. The binding of SY5Y tau to taxol-stabilized microtubules
It has been previously reported that tau in SY5Y cells is not
associated with microtubules in vitro and does not bind to
taxol-stabilized microtubules [11]. In the present study, we
show that the microtubule binding activity of SY5Y tau was
fully restored after dephosphorylation (Fig. 2). Only about
10% of untreated SY5Y tau bound to taxol-stabilized micro-
tubules, whereas after dephosphorylation by alkaline phos-
phatase, more than 95% of dephosphorylated SY5Y tau was
bound.
3.3. Inhibition of tau-promoted microtubule assembly by SY5Y
tau
Previously, we demonstrated that in vitro AD P-tau seques-
ters normal tau and thus inhibits the tau-promoted microtu-
bule assembly [4]. To investigate whether SY5Y tau, which is
hyperphosphorylated at several of the same sites as AD P-tau,
has the same characteristics as AD P-tau, SY5Y tau was
added together with recombinant tau to promote microtubule
assembly. As shown in Fig. 3A, SY5Y tau as well as AD P-
tau inhibited the microtubule assembly-promoting activity of
recombinant tau. About 20 Wg/ml of SY5Y tau was required
to partially inhibit the microtubule assembly and about 60Wg/
ml of SY5Y tau completely inhibited the microtubule assem-
bly promoted by 100 Wg/ml of tau410, while for AD P-tau 20
Wg/ml was su⁄cient to obtain the full inhibition (data not
shown). When SY5Y tau was dephosphorylated in vitro and
then added together with recombinant tau to tubulin, there
was no inhibition of the microtubule assembly even when up
to 90 Wg/ml dephosphorylated SY5Y tau was added. Almost
no microtubules were found by electron microscopy in experi-
ments with recombinant tau and SY5Y tau added together,
whereas many microtubules were observed when the assembly
was carried out with dephosphorylated SY5Y tau and re-
Fig. 2. Microtubule binding activity of SY5Y tau. SY5Y tau (0.6
Wg) with or without pretreatment with alkaline phosphatase was in-
cubated with 50 Wg of taxol-stabilized microtubules in MES bu¡er
containing 10 WM taxol at 37‡C for 30 min. The microtubule pellet
was separated by centrifugation over a 10% sucrose cushion at
60 000Ug for 30 min. The supernatant containing the unbound pro-
teins (U) and the pellet containing the stabilized microtubules with
microtubule bound proteins (B) were analyzed by immunoblots
probed with anti-tau polyclonal antibody, R134d (1:5000). SY5Y
tau bound to microtubules only after dephosphorylation by alkaline
phosphatase.
Fig. 3. The e¡ect of SY5Y tau on the tau-promoted microtubule
polymerization. A: Turbidimetric assay measuring microtubule as-
sembly using recombinant and SY5Y tau. Bovine brain tubulin (2
mg/ml), recombinant human tau410 (100 Wg/ml), GTP (1 mM) in
100 mM MES, 1 mM EGTA, 1 mM MgCl2, pH 6.8, and SY5Y
tau were mixed and the turbidimetric changes at 350 nm recorded
in a Cary 1 spectrophotometer at 37‡C. Curve 1, tau410, 100 Wg/ml
(recombinant tau with two N-terminal inserts and three microtubule
binding repeats); 2, dephosphorylated SY5Y tau (90 Wg/ml) plus
100 Wg/ml tau410 ; 3, untreated SY5Y tau (20 Wg/ml) plus 100 Wg/ml
tau410 ; 4,dephosphorylated SY5Y tau (90 Wg/ml) without tau410 ; 5,
bovine brain tubulin control. B: Electron micrographs showing
products of microtubule assembly reaction. Assembly from bovine
brain tubulin promoted by tau410 in the presence of dephosphoryl-
ated SY5Y tau (left panel) or untreated (right panel). Samples were
taken at steady state of polymerization and were negatively stained
with phosphotungstic acid.
Table 1
Levels of microtubule-associate proteins in SY5Y cells and in AD brain
SY5Y cells (n = 3) AD brain (n = 5)
Tau (PSL/Wg) (mean þ S.D.) 37.6 þ 4.6 418.1 þ 109.8
MAP1B (PSL/Wg) (mean þ S.D.) 96.3 þ 1.9 51.9 þ 11.4
MAP1 (PSL/Wg) (mean þ S.D.) 17.9 þ 1.4 18.5 þ 4.9
MAP2 (PSL/Wg) (mean þ S.D.) 25.5 þ 2.8 31.9 þ 3.9
Tau/MAP1B 0.39 8.05
(relative percentage) (4.8%) (100%)
Tau/MAP1 2.1 22.6
(relative percentage) (9.3%) (100%)
Tau/MAP2 1.47 13.1
(relative percentage) (11.2%) (100%)
MAPs were quantitated in SY5Y cells and brain homogenates by radioimmunodot-blot assays using Tau-1 (1:50 000, after dephosphorylation
on the blot), anti-MAP2 (1:1000), anti-MAP1 (1:1000) and anti-MAP1B (1:250) antibodies. The values are expressed as relative mean immu-
noreactivities (PSL) per Wg protein þ S.D. of SY5Y cells of three individual culture dishes and brain samples from ¢ve di¡erent AD cases.
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combinant tau (Fig. 3B). However, in contrast to AD P-tau,
when SY5Y tau was dephosphorylated, it even at 90 Wg/ml
was not able either to increase the polymerization of micro-
tubules when added together with tau410 or to promote the
polymerization on its own. A second tau preparation from
another batch of cells produced almost identical results.
3.4. Comparison of the levels of tau and other MAPs between
SY5Y cells and AD brain
Although tau in SY5Y cells is similarly hyperphosphoryl-
ated as tau in AD brain, SY5Y cells have an intact micro-
tubule network and proliferate normally. To study why the
endogenous hyperphosphorylated tau is not cytotoxic to
SY5Y cells, the levels of tau and other MAPs both in SY5Y
cells and AD brain were determined by radioimmunodot-blot
assays. Table 1 shows that the level of tau protein was about
10 times less in SY5Y cells than in AD brain, whereas the
levels of MAP2 and MAP1B in SY5Y cells were similar or
higher than in AD brain.
4. Discussion
Tau, a major neuronal MAP, promotes microtubule assem-
bly and stabilizes microtubules in vitro, and is believed to
maintain the microtubule network of the neuron [25^27].
The abnormal hyperphosphorylation of tau protein is thought
to be an important initial event in neurodegeneration in AD
brain, because the AD hyperphosphorylated tau is not only
unable to promote microtubule assembly but instead it inhib-
its the assembly and disassembles already assembled micro-
tubules by sequestering normal tau, MAP1 and MAP2 in
vitro [4,6]. Furthermore, ultrastructural examination of brain
biopsies from AD patients has revealed disruption and re-
placement of the microtubule network with paired helical ¢l-
aments and condensation in some areas of the mitochondria
and liposomes, all reminiscent of neurodegeneration due to
inhibition of the axoplasmic transport [28]. Braak et al. [29]
have also demonstrated initial stages of retrograde degenera-
tion of neurons with abnormally hyperphosphorylated tau in
60 Wm thick sections of entorhinal cortex of very early cases of
AD.
Tau in SY5Y cells is hyperphosphorylated at some of the
same sites as AD P-tau and, like AD P-tau, does not bind to
microtubules [11], but it does not seem to destroy the micro-
tubule network of the cell. One reason for this discrepancy
might be insu⁄cient phosphorylation at sites critical for con-
verting tau into a toxic molecule. Phosphorylation of tau at
Ser-262, the 12E8 epitope, has been shown to be a strong
determinant for the binding of tau to microtubules [30], but
phosphorylation at additional sites like Thr-231/Ser-235, Ser-
396/404 and Ser-214 seem to be required for the full inactiva-
tion of the biological activity of tau [17,31^33]. SY5Y tau not
only does not bind to taxol-stabilized microtubules but also
fully inhibits tau-promoted microtubule assembly in vitro,
although about three times more SY5Y tau was required to
achieve the same inhibition as AD P-tau. These data show
that in comparison to AD P-tau, only about one third of
the SY5Y tau is hyperphosphorylated su⁄ciently to inhibit
the microtubule assembly.
The data in the present study show that in the case of SY5Y
tau and as well as AD P-tau, both the inhibition of micro-
tubule assembly and loss of microtubule binding activity are
due to hyperphosphorylation of SY5Y tau. However, in con-
trast to the dephosphorylated AD P-tau, the dephosphoryl-
ated SY5Y tau was not capable of inducing nucleation of
microtubules. Nucleation, elongation and microtubule binding
activities are believed to be distinct aspects of tau function.
Mutation or phosphorylation in the amino-terminal £anking
region of the microtubule binding domain of tau can selec-
tively reduce the microtubule nucleating ability of tau [34,35].
The exact cause of the inability of the dephosphorylated
SY5Y tau to promote microtubule assembly is currently not
understood.
Obviously tau’s hyperphosphorylation did not seem to af-
fect the maintenance of the microtubule network of SY5Y
cells, most likely because of the low concentration of tau as
compared to that in the AD brain. SY5Y cells contain only
one tenth of tau but almost the same levels of the other HMW
MAPs as the AD brain. Thus in SY5Y cells, instead of tau,
the other HMW MAPs, especially MAP1B and MAP2 are the
dominant microtubule-associated proteins that promote and
stabilize the microtubule system. In the light of the low a⁄n-
ity of hyperphosphorylated tau towards HMW MAPs [6], it
seems most likely that the concentration of hyperphospho-
rylated tau in SY5Y cells is insu⁄cient to fully sequester the
other MAPs to induce microtubule breakdown. However, the
possibility that a modi¢cation other than the phosphorylation
of tau in SY5Y cells might prevent it from causing degener-
ation of these cells cannot be eliminated.
Abnormal phosphorylation of tau is believed to be an early
step and a main cause of the breakdown of the neuronal
microtubule network and neuro¢brillary degeneration in
AD. Our study indicates that the breakdown of the micro-
tubule network induced by abnormally hyperphosphorylated
tau is not only dependent on the phosphorylation of tau, but
also on the ratio of hyperphosphorylated tau protein to other
HMW MAPs. SY5Y cells have been widely used as a model
to study Alzheimer-like tau phosphorylation. The present
study illustrates, as an experimental cell model for Alzheimer
neuro¢brillary degeneration, the limitations of this cell line,
and probably also other cell lines derived from cancerous
tissue, most of which have low tau content.
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